Emerging Indications for Radiation in Poly-Metastatic Cancers

This activity focuses on new and emerging indications for radiation in patients with metastatic cancers. The speakers discuss the use of radiation to achieve patient-centered goals, including extending survival, preventing complications (such as fractures from bony metastases, or morbidity from progression of primary tumors), and preserving quality of life. Each lecture includes a brief review of recent evidence, followed by practical advice for physicians who may wish to either 1) implement radiation for a new indication in their clinical practice, or 2) design or implement clinical trials at their center for that indication.

Topics:

  1. ARRESTing More Than 10 Lesions with SABR: Insights from the ARREST and ARREST 2 Trials
    Tim Nguyen, MD
  2. HALTing Oligoprogressive Cancers
    Fiona McDonald, MBBS, MA, MRCP, FRCR, MD(Res)
  3. Integrating SABR with Immunotherapy and Other New Agents
    Jonathan Schoenfeld, MD, MPH
  4. Radiating High-Risk Tumors in the Metastatic Setting: Different Strokes for Different Folks
    Melvin Lee Kiang Chua, MBBS, PhD, FRCR
  5. Beaming Into the Future: How Do We Generate Evidence to Support New Indications?
    David A. Palma, MD, PhD, MSc., FRCPC
  6. Panel Discussion
    David A. Palma, MD, PhD, MSc., FRCPC - Moderator
    Full Panel

This activity is available from March 10, 2026, through 11:59 p.m. Eastern time on March 9, 2028. 

The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.

Target Audience

The activity is designed to meet the interests of radiation oncologists, physicists, radiation therapists and radiation dosimetrists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement treatment for the new indications for radiation that are already established, as discussed by the speakers. 
  • Identify promising areas and potential future indications for radiation, and begin processes to implement these in the future if desired (e.g., begin to build necessary multidisciplinary collaborations at their center).
  • Better implement, analyze and discuss future trials of new technologies in radiation oncology, in light of the challenges in conducting radiation-related randomized trials.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
03/10/2026
Course expires: 
03/09/2028
Cost:
$149.00
Rating: 
0

Moderator: 

  • David A. Palma, MD, PhD, MSc, FRCPC, is employed by London Health Sciences Centre. Dr. Palma receives honoraria from Need, Inc. and UpToDate. Dr. Palma owns stock in Need, Inc. 

Speakers:

  • Tim Nguyen, MD, is employed by London Health Sciences Centre. Dr. Nguyen receives compensation/payment from Need, Inc.  
  • Fiona McDonald, MBBS, MA, MRCP, FRCR, MD(Res), is employed by The Royal Marsden NHS Foundation Trust. Dr. McDonald has no relevant financial relationship with ineligible companies to disclose.   
  • Jonathan D. Schoenfeld, MD, MPH, is employed by Dana-Farber Cancer Institute, Harvard Medical School. Dr. Schoenfeld receives grant/research funding from Bristol Myers Squibb, EMD Serono, Merck and Regeneron. Dr. Schoenfeld receives compensation/payment from Immunitas and Merck KGaA and owns stock options in Immunitas.  
  • Melvin Lee Kiang Chua, MBBS, PhD, FRCR, is employed by National Cancer Centre Singapore. Dr. Chua receives grant/research funding from Bayer, BeiGene and Decipher Bioscience. Dr. Chua receives travel expenses and/or honoraria from Astellas, AstraZeneca, Janssen, Pfizer, Novartis and Bicara. Dr. Chua serves in uncompensated roles with ImmunoSCAPE, IQVIA and MSD. Dr. Chua receives in-kind donations from PVMed and owns stock in Digital Life Line.  

Planners: 

  • Malcolm Mattes, MD is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $149
  • Member: $99
  • Member-in-Training: $49
  • Student/Graduate Student/PGY-1 Member: $49
  • Postdoctoral Fellow Member: $49

If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until March 9, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.